Chemokines in Behçet’s Disease, a Field to Be Explored as a Potential Basis for Therapy

  • Marco Baggiolini
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 528)


Human Immunodeficiency Virus Familial Mediterranean Fever Multiple Receptor Inflammatory Chemokines Polycyclic Compound 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Zouboulis, Ch.C., and Keitel, W., 2002, A Historical review of early descriptions of Adamantiades-Behçet’s disease. J. Invest. Dermatol. 119: 201–205.CrossRefPubMedGoogle Scholar
  2. 2.
    Mege, J.L., Dilsen, N., Sanguedolce, V., et al., 1993, Overproduction of monocyte derived tumor necrosis factor α interleukin (IL) 6; IL-8 and increased neutrophil superoxide generation in Behçet’s disease: a comparative study with familial Mediterranean fever and healthy subjects. J. Rheumatol. 20: 1544–1549.PubMedGoogle Scholar
  3. 3.
    Itoh, R., Takenaka, T., Okitsu-Negishi, S., et al., 1994, Interleukin-8 in Behçet’s disease. J. Dermatol. 21: 397–404.PubMedGoogle Scholar
  4. 4.
    al-Dalaan, A., al-Sedairy, S., al-Balaa, S., et al., 1995, Enhanced interleukin 8 secretion in circulation of patients with Behçet’s disease. J. Rheumatol. 22: 904–907.PubMedGoogle Scholar
  5. 5.
    Zouboulis, Ch.C., Katsantonis, J., Ketteler, R., et al., 2000, Adamantiades-Behçet’s disease: Interleukin-8 is increased in serum of patients with active oral and neurological manifestations and is secreted by small vessel endothelial cells. Arch. Dermatol. Res. 292: 279–284.CrossRefPubMedGoogle Scholar
  6. 6.
    Sahin, S., Lawrence, R., Direskeneli, H., et al., 1996, Monocyte activity in Behçet’s disease. Br. J. Rheumatol. 35: 424–429.PubMedGoogle Scholar
  7. 7.
    Baggiolini, M., Walz, A., and Kunkel, S.L., 1989, Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J. Clin. Invest. 84: 1045–1049.PubMedGoogle Scholar
  8. 8.
    Baggiolini, M., Dewald, B., and Moser, B., 1994, Interleukin-8 and related chemotactic cytokines — CXC and CC chemokines. Adv. Immunol. 55: 97–179.PubMedGoogle Scholar
  9. 9.
    Baggiolini, M., 1998, Chemokines and leukocyte traffic. Nature 392: 565–568.CrossRefPubMedGoogle Scholar
  10. 10.
    Loetscher, P., Moser, B., and Baggiolini, M., 2000, Chemokines and their receptors in lymphocyte traffic and HIV infection. Adv. Immunol. 74: 127–180.PubMedGoogle Scholar
  11. 11.
    Murphy, P.M., Baggiolini, M., Charo, I.F., et al. 2000, International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 52: 145–176.PubMedGoogle Scholar
  12. 12.
    Zlotnik, A., and Yoshie, O., 2000, Chemokines: a new classification system and their role in immunity. Immunity 12: 121–127.CrossRefPubMedGoogle Scholar
  13. 13.
    Gerard, C., and Rollins, B.J., 2001, Chemokines and disease. Nature Immunol. 2: 108–115.Google Scholar
  14. 14.
    Clark-Lewis, I., Schumacher, C., Baggiolini, M., et al., 1991, Structure-activity relationships of interleukin-8 determined using chemically synthesized analogs. Critical role of NH2-terminal residues and evidence for uncoupling of neutrophil chemotaxis, exocytosis, and receptor binding activities. J. Biol. Chem. 266: 23128–23134.PubMedGoogle Scholar
  15. 15.
    Clark-Lewis, I., Dewald, B., Geiser, T., et al., 1993, Platelet factor 4 binds to interleukin 8 receptors and activates neutrophils when its N terminus is modified with Glu-Leu-Arg. Proc. Natl. Acad. Sci. USA 90: 3574–3577.PubMedGoogle Scholar
  16. 16.
    Hébert, C.A., Vitangcol, R.V., and Baker, J.B., 1991, Scanning mutagenesis of interleukin-8 identifies a cluster of residues required for receptor binding. J. Biol. Chem. 266: 18989–18994.PubMedGoogle Scholar
  17. 17.
    Baggiolini, M., Dewald, B., and Moser, B., 1997, Human chemokines: An update. Annu. Rev. Immunol. 15: 675–705.CrossRefPubMedGoogle Scholar
  18. 18.
    Berger, E.A., Murphy, P.M., and Farber, J.M., 1999, Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17: 657–700.CrossRefPubMedGoogle Scholar
  19. 19.
    Arenzana-Seisdedos, F., Virelizier, J.L., Rousset, D., et al. 1996, HIV blocked by chemokine antagonist. Nature 383: 400.CrossRefPubMedGoogle Scholar
  20. 20.
    Crump, M.P., Gong, J.H., Loetscher, P., et al., 1997, Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J. 16: 6996–7007.CrossRefPubMedGoogle Scholar
  21. 21.
    Gong, J.-H., Ratkay, L.G., Waterfield, J.D., et al., 1997, An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J. Exp. Med. 186: 131–137.CrossRefPubMedGoogle Scholar
  22. 22.
    Plater-Zyberk, C., Hoogewerf, A.J., Proudfoot, A.E.I., et al., 1997, Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice. Immunol. Lett. 57: 117–120.CrossRefPubMedGoogle Scholar
  23. 23.
    Horuk, R., and Ng, H.P., 2000, Chemokine receptor antagonists. Med. Res. Rev. 20: 155–168.CrossRefPubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Marco Baggiolini
    • 1
  1. 1.Institute for Research in BiomedicineBellinzona and University of LuganoSwitzerland

Personalised recommendations